Micropore AXF range for the continuous production of stable nanomedicines

Click2Contact

ATA Scientific has announced that it has entered a partnership with Micropore Technologies, innovators of advanced membrane-based crossflow technology for scalable engineered particles.

As the development of new drugs and delivery systems accelerates, particularly after the remarkable success of mRNA-LNP technology, so too must strategies for faster, efficient and scalable drug manufacturing. Currently nanoparticle drugs are produced using methods such as lipid hydration, extrusion or impingement jet mixing (IJM), but these suffer from turbulent mixing and multiple harsh processing steps which compromise stability and give high batch variability. Microfluidic mixing offers rapid formulation with low polydispersity but again cannot accommodate high-volume production.

Expected to make a significant contribution to improving the performance of entire nanoparticle manufacturing process, Micropore’s AXF range offers seamless scalability from initial R&D (0.2 mL) to final pandemic-scale GMP manufacturing (1500 L/h). This translates to 58,000 doses of vaccine every minute from a device small enough to fit in the palm of the hand.

Collaborations with The University of Strathclyde and Professor Yvonne Perrie demonstrated mRNA encapsulation efficiencies over 97% in LNP production using AXF advanced crossflow mixing. This demonstrates that the AXF can provide efficient mass production of a new generation of LNP-based therapeutics. The series is designed to be easy to operate and stable in operation.

For more information: https://www.atascientific.com.au/ata-scientific-partners-with-micropore-technologies/.